Prestige Consumer Healthcare (Prestige Consumer Healthcare) ROCE %

: 10.74% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Prestige Consumer Healthcare's annualized ROCE % for the quarter that ended in Dec. 2023 was 10.74%.

Prestige Consumer Healthcare ROCE % Historical Data

The historical data trend for Prestige Consumer Healthcare's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Consumer Healthcare Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

1.93

8.61

8.59

9.56

-0.74

Prestige Consumer Healthcare Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																9.67	-33.09	10.82	11.00	10.74

Prestige Consumer Healthcare ROCE % Calculation

Prestige Consumer Healthcare's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-24.751	/	( ( (3670.681 - 143.422)	+	(3353.729 - 160.715) )	/ 2 )
	=	-24.751	/	( (3527.259	+	3193.014)	/ 2 )
	=	-24.751	/	3360.1365
	=	-0.74 %

Prestige Consumer Healthcare's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	344.6	/	( ( (3332.874 - 129.704)	+	(3339.753 - 127.437) )	/ 2 )
	=	344.6	/	( ( 3203.17	+	3212.316 )	/ 2 )
	=	344.6	/	3207.743
	=	10.74 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Prestige Consumer Healthcare (NYSE:PBH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Prestige Consumer Healthcare ROCE % Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PBV:Germany

Address

660 White Plains Road, Tarrytown, NY, USA, 10591

Website

https://www.prestigebrands.com

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Executives

Mary Beth Fritz	officer: Senior VP Quality & Regulatory	660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi	officer: Chief Executive Officer	660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca	director	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco	officer: Chief Financial Officer	C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail	other: EVP, Marketing & Sales	660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool	officer: See Remarks	2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark	director	C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin	director
Natale S Ricciardi	director	C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness	director	PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom	director	660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins	director	C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier	director	600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo	officer: Senior VP Operations	660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors	officer: Chief Marketing Officer	660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591